CD8A and prostate neoplasm: Indeed, 2-D08 combined with anti–PD-1 therapy remarkably suppressed prostate tumor progression along with a more pronounced increase of CD8+ T cell frequency and a higher percentage of IFN-γ+ CD8+ T cells in the prostate tumors.